Ivabradine for treating chronic heart failure

life. It also noted the comment from the patient experts that chronic heart failure can impact on everyday tasks, with comorbidities increasing the impact of the disease and usually requiring lifestyle changes. The patient experts also stated that ivabradine may provide symptomatic and prognostic benefit in a small number of chronic heart failure patients unable to take beta-blockers. The committee considered the clinical specialists' comment that it may be difficult to increase beta-blocker dosage for people with low blood pressure, a group who would benefit from ivabradine. It noted that ivabradine is contraindicated in severe hypotension (less than 90/ 50 mmHg). The committee recognised the impact of chronic heart failure on quality of life and concluded that there were potential treatment benefits with ivabradine for people who are covered by the marketing authorisation. 4.3 The committee considered the generalisability of the SHIFT trial to UK clinical practice. The committee was aware that the population covered by the marketing authorisation in SHIFT was younger, included a higher proportion of men and people with more severe chronic heart failure than the typical chronic heart failure population in the UK. It also noted that only a few people from the UK were included
